Zobrazeno 1 - 2
of 2
pro vyhledávání: '"María Ruíz de Arcos"'
Autor:
Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses. The objective of this study was to describe the
Externí odkaz:
https://doaj.org/article/094fc9f9f7414c1781855e49921d42f0
Autor:
Santos García D., Teresa de Deus Fonticoba, Carlos Cores, Guillermo Muñoz, Jose M. Paz González, Cristina Martínez Miró, Ester Suárez, Silvia Jesús, Miquel Aguilar, Pau Pastor, Lluis Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Inés Legarda, Jorge Hernández Vara, Iria Cabo, Luis López Manzanares, Isabel González Aramburu, María A. Ávila Rivera, Maria J. Catalán, Víctor Nogueira, Víctor Puente, María Ruíz de Arcos, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Pedro Clavero, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Carlos Ordás, Luis M. López Díaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, COPPADIS Study Group
Publikováno v:
npj Parkinson's Disease, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment i
Externí odkaz:
https://doaj.org/article/f6dde4dc0dad4c5f8c95e81a9fb5163e